Padcev-Imfinzi Cuts Bladder Cancer Death Risk 42%; Blackstone Backs Obesity Drug With $1.5B
PFE sits 23% above its 52-week low of $23.62.
Summary
Pfizer's Padcev, paired with AstraZeneca's Imfinzi before surgery, cut death risk 42% versus surgery alone in a nearly 700-patient bladder cancer trial, with two-year survival of 78% versus 69%. Separately, Blackstone-managed funds committed up to $1.5 billion through 2028 to develop the obesity drug berobenatide, with Pfizer keeping control and payments tied to U.S. approval and sales milestones. The same drug showed 15.9% weight loss after 32 weeks in the Phase 2b VESPER-1 extension, with no plateau, while the Phase 3 VESPER-6 monthly-dosing trial is enrolling. Pfizer is also seeking about €1.3 billion from Poland for unpaid COVID-19 vaccine orders, a Brussels court having overturned a seizure of PANSA transit-fee revenue in a ruling that is not final. The pipeline news lands after the Nov. 3 raise of 2026 revenue guidance to $62.0-64.0 billion and adjusted EPS to $2.95-3.05, and the obesity data plus outside funding matter most for the post-COVID growth story.
At the time of this announcement, PFE was trading at $29.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $164.7B. The 52-week trading range was $23.62 to $31.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.